Research
/
Stock
/
ABT
A
ABT
ABBOTT LABORATORIES
FY2025
i
Mkt cap 201.8B
116.13
-0.54 -0.46%
close 2026-08-25
i
Overview
Financials
Insider
DCF
Research
/
Stock
/
…
Pulling SEC filings & building this page… the first lookup of a new ticker takes a few seconds, then it's cached.
Mkt Cap
i
201.8B
P/E
i
31.2
Revenue FY2025
i
44.3B
Gross Margin
i
56.4%
FCF FY2025
i
7.4B
Net Income
i
6.5B
52-week range
i
82.56
-15.0% off high
i
136.62
Beta
i
0.50
vs S&P 500 · 1254 common days
Dividend
i
2.04%
$4.1B paid in FY2025 · on today's cap
Price
i
1M
6M
1Y
5Y
i
i
Revenue
i
44.3B
FY2025
i
·
+5.7% YoY
i
i
EBITDA
i
11.2B
FY2025 · operating + D&A
Free Cash Flow
i
7.4B
FY2025
i
·
+16.4% YoY
i
i
EPS (diluted)
i
3.72
FY2025
i
·
-51.3% YoY
i
i
Earnings
i
next est.
Last reported
16 Jul 2026 · 8-K (2.02)
Next report
≈ 15 Oct 2026
Moat & Risks
i
Engine pending
56.4% gross margin (FY2025) — pricing-power signal.
FY2025 10-K ›
Revenue +5.67% YoY to 44.3B (FY2025).
FY2025 10-K ›
Sourced moat / risk brief — generated by the Silkcodex engine (pending run).
Insider activity
i
Section 16
i
All transactions →
No Form 4 filings on file. Most foreign private issuers are exempt from Section 16, and coverage of the rest is a capped recent window — an empty panel is not evidence of no insider activity.
Recent filings
SEC EDGAR
i
No filings on file.